Trump Announces Deals With Eli Lilly, Novo Nordisk for Lower Weight Loss Drug Prices

The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the costs of the nation’s 2 highest-expenditure drugs, both in-demand glucagon-like peptide-1 (GLP-1) receptor agonists used for diabetes, heart disease, and obesity management, among other conditions.¹

The announcement advances President Donald Trump’s Most Favored Nation (MFN) executive order, which aims to address the disparity in drug pricing in the US vs other wealthy nations.² Pfizer and AstraZeneca also recently struck deals with the administration, both of which were voluntary agreements complying with the MFN order.^2,3

Novo Nordisk’s semaglutide agents (Ozempic and Wegovy) will see their monthly prices reduced from approximately $1000 and $1350, respectively, to $350 when purchased through TrumpRx, a new government website set to launch in 2026 that will allow Americans to purchase medicine directly from pharmaceutical companies at substantial discounts.^1,3

Eli Lilly’s high-profile obesity treatment tirzepatide (Zepbound) and its potential oral GLP-1 counterpart, orforglipron, if approved, will see monthly prices drop from more than $1080 to an average of $346 when purchased through TrumpRx.¹ The initial dose of any future FDA-approved oral GLP-1 drugs will be priced at $150 per month from either manufacturer.

Under the new agreement, Medicare and state Medicaid program prices of Ozempic, Wegovy, Zepbound, and Mounjaro (tirzepatide for diabetes) will be $245. Additionally, Medicare will cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time. Medicare beneficiaries will pay a co-pay of $50 per month.

The agreement extends beyond GLP-1s, with Novo Nordisk committing to providing its widely used insulin products, including NovoLog and Tresiba, at a maximum of $35 per month of supply. Eli Lilly has agreed to discounts on treatments like migraine medication galcanezumab (Emgality) and diabetes medication dulaglutide (Trulicity), bringing them to $299 and $389 per month, respectively.

Eli Lilly and Novo Nordisk also guaranteed MFN pricing on all new medications brought to market and to provide every state Medicaid program access to MFN prices on their products under the new agreement.

References

1. Fact sheet: President Donald J. Trump announces major developments in bringing most-favored-nation pricing to American patients. WhiteHouse.gov. November 6, 2025. Accessed November 6, 2025. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/

2. Mattina C. White House to announce second drug pricing deal as AstraZeneca joins TrumpRx. AJMC^®. October 10, 2025. Accessed November 6, 2025. https://www.ajmc.com/view/white-house-to-announce-second-drug-pricing-deal-as-astrazeneca-joins-trumprx

3. Joszt L. White House, Pfizer reach agreement on drug discounts; Trump announces TrumpRx. AJMC. September 30, 2025. Accessed October 10, 2025. https://www.ajmc.com/view/white-house-pfizer-reach-agreement-on-drug-discounts-trump-announces-trumprx